Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03719573
Other study ID # 123
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 21, 2019
Est. completion date May 10, 2022

Study information

Verified date August 2022
Source Herlev and Gentofte Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The GEPOC study investigates the effect of comprehensive geriatric assessment and intervention for frail older patients (65 years or older) undergoing elective surgery for colorectal cancer. the geriatric intervention will be pre- and postoperative. included in the intervention is an exercise intervention. The main aim of the study us to see if the functional decline in this group can be reduced.


Description:

This is a randomized, controlled trial on frail older patients (aged 65 years or older) with colorectal cancer. The patients will be randomized into two groups. The control group will receive standard surgical treatment. The intervention group will in addition go through a preoperative comprehensive geriatric assessment. The assessment will include evaluation of co-morbidity and medication, social status, nutritional status, cognition, depression and physical performance. This assessment will form basis of an individualized intervention. Patients in the intervention group will participate in planned exercise programs before surgery, perioperative and postoperative.


Recruitment information / eligibility

Status Completed
Enrollment 67
Est. completion date May 10, 2022
Est. primary completion date May 10, 2022
Accepts healthy volunteers No
Gender All
Age group 65 Years and older
Eligibility Inclusion Criteria: - elective surgery for colorectal cancer - frail - ability to read and speak danish (informed concent) Exclusion Criteria: - any physical condition that hinder physical exercise (eg. no legs) - not able to concent

Study Design


Intervention

Other:
Geriatric intervention
A comprehensive geriatric assessment (CGA), focusing on co-morbidity, medication, cognitive status, depression, nutritional status and physical status is performed. The intervention is individualized according to the results of the CGA.

Locations

Country Name City State
Denmark Herlev and Gentofte Hospital Herlev Region H

Sponsors (3)

Lead Sponsor Collaborator
Herlev and Gentofte Hospital University of Copenhagen, Velux Fonden

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary 30-second chair stand test (30s-CST) functional test measuring lower body strength baseline to 14 weeks after surgery
Secondary physical function and capacity - 6-minute-walk-test 6-minute-walk-test baseline to 14 weeks after surgery
Secondary physical function and capacity - hand grip strength hand grip strength baseline to 14 weeks after surgery
Secondary physical function and capacity - 6-meter gait speed 6-meter gait speed baseline to 14 weeks after surgery
Secondary Patient reported Quality of Life: EORTC EORTC European Organisation for Research and Treatment of Cancer questionnaire C30 (30-126 points where 30 is the worst) baseline to 14 weeks after surgery
Secondary Patient reported Quality of Life: EORTC ELD14 EORTC European Organisation for Research and Treatment of Cancer questionnaire conjoined with ELD14 (Elderly Cancer Patient module) (14-54 points where 54 is the worst) baseline to 14 weeks after surgery
Secondary Quality of recovery after surgery: questionnaire Measured with the questionnaire: Quality of Recovery - 15 questionnaire (0-150 points where 0 points is the worst) 1 day before surgery (baseline) to 3 days after surgery
Secondary body composition measured by Bioimpedance assessment baseline to 14 weeks after surgery.
Secondary body composition measured by dual-energy x-ray absorptiometry baseline to 14 weeks after surgery.
Secondary inflammatory biomarker - CRP the concentration of CRP (CRP C-reactive Protein) baseline to 14 weeks after surgery
Secondary inflammatory biomarker - Interleukin 6 the concentration of interleukin 6 baseline to 14 weeks after surgery
Secondary inflammatory biomarker YKL-40 the concentration of YKL-40 (YKL-40 is also known as Chitinase-3-like protein 1) baseline to 14 weeks after surgery
Secondary inflammatory biomarkers immuno-oncology the concentration of 92 proteins associated with immuno-oncology (OLink) baseline to 14 weeks after surgery
Secondary sarcopenia biomarker GDF-11 the concentration of GDF-11 (GDF Growth Differentiation Factor) baseline to 14 weeks after surgery
Secondary sarcopenia biomarker GDF the concentration of GDF-15 (GDF Growth Differentiation Factor) baseline to 14 weeks after surgery
Secondary Postoperative complications Measured with Clavien Dindo classification (grade I-V where grade V is death) 30 days + 90 days
Secondary readmission Number of patients being readmitted to hospital within 30 + 90 days after operation for colon surgery. 30 days after surgery and 90 days after surgery
Secondary survival number of survivors after surgery 10 years
Secondary mortality number of patients death baseline to 3 months
Secondary number of patients to start up of adjuvant chemotherapy after surgery. according to guidelines, if physical condition allows it (and patient accepts it). 14 weeks
Secondary start up time of adjuvant chemotherapy after surgery measured in days (if relevant) 14 weeks
Secondary number of series of adjuvant chemotherapy 14 weeks
Secondary doses of adjuvant chemotherapy 14 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Completed NCT00098787 - Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05425940 - Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer Phase 3
Suspended NCT04595604 - Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery. N/A
Completed NCT03414125 - Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening N/A
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Terminated NCT01847599 - Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib N/A
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Recruiting NCT03874026 - Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT03181334 - The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation N/A
Completed NCT03167125 - Participatory Research to Advance Colon Cancer Prevention N/A
Recruiting NCT04258137 - Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study N/A
Recruiting NCT05568420 - A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
Recruiting NCT02972541 - Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer N/A
Completed NCT02876224 - Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors Phase 1
Completed NCT01943500 - Collection of Blood Specimens for Circulating Tumor Cell Analysis N/A